◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SIBN

Si-Bone Inc (SIBN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-09-19

Si-Bone Inc (SIBN) operates in the MEDICAL DEVICES industry and is headquartered in Santa Clara, United States with about 376 employees. Its market capitalization is roughly $824 million. In the fiscal year ended 2025-12-31, SIBN reported $201M in revenue and ($19M) in net income.

SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.

Interactive charts & full statements → Open the SIBN valuation workbench →

SIBN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$214M	$201M	$167M	$139M	$106M	$90M	$73M	$67M	$55M	$48M	$42M	$41M	$40M	$49M	$37M
Gross Profit	$170M	$160M	$132M	$109M	$91M	$80M	$64M	$61M	$51M	$43M	$37M	$36M	$34M	$45M	$34M
Gross Margin %	79.5%	79.6%	79.0%	78.8%	85.2%	88.4%	87.9%	89.9%	91.3%	89.3%	87.7%	86.9%	83.8%	91.2%	91.8%
Operating Income (EBIT)	($18M)	($22M)	($35M)	($47M)	($60M)	($52M)	($39M)	($36M)	($12M)	($17M)	($18M)	($26M)	($26M)	($5M)	($11M)
Operating Margin %	-8.3%	-11.1%	-21.1%	-33.8%	-56.0%	-57.3%	-52.5%	-53.5%	-21.6%	-36.2%	-41.7%	-64.2%	-65.7%	-10.8%	-29.0%
Net Income	($15M)	($19M)	($31M)	($43M)	($61M)	($57M)	($44M)	($38M)	($17M)	($23M)	($21M)	($28M)	($28M)	($6M)	($11M)
Net Margin %	-6.9%	-9.4%	-18.5%	-31.2%	-57.6%	-62.7%	-59.5%	-57.1%	-31.5%	-48.0%	-48.9%	-68.4%	-69.4%	-12.6%	-29.4%
EBITDA	($5M)	($11M)	($23M)	($34M)	($55M)	($51M)	($36M)	($33M)	($11M)	($16M)	($16M)	($26M)	($26M)	($5M)	($11M)
Earnings Per Share (EPS)	$-0.33	$-0.43	$-0.75	$-1.13	$-1.79	$-1.71	$-1.50	$-1.55	$-1.10	$-1.66	$-1.33	$-1.17	$-10.42	$-2.69	$-5.76
Shares Outstanding (M)	44M	44M	41M	38M	34M	33M	29M	25M	16M	14M	15M	24M	3M	2M	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SIBN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$56M	$53M	$56M	$49M	$49M	$47M	$49M	$40M
Gross Profit	$45M	$42M	$45M	$39M	$39M	$38M	$39M	$32M
Gross Margin %	79.5%	79.8%	79.0%	79.8%	79.8%	79.7%	79.1%	79.1%
Operating Income (EBIT)	($5M)	($5M)	($2M)	($5M)	($7M)	($7M)	($5M)	($8M)
Operating Margin %	-8.6%	-9.7%	-4.4%	-11.1%	-14.4%	-15.8%	-11.2%	-18.9%
Net Income	($4M)	($4M)	($2M)	($5M)	($6M)	($7M)	($4M)	($7M)
Net Margin %	-7.3%	-8.2%	-2.9%	-9.4%	-12.7%	-13.8%	-9.2%	-16.3%
EBITDA	($3M)	($2M)	$3M	($2M)	($4M)	($5M)	($2M)	($5M)
Earnings Per Share (EPS)	$-0.09	$-0.10	$-0.04	$-0.11	$-0.14	$-0.15	$-0.11	$-0.16
Shares Outstanding (M)	44M	44M	44M	43M	43M	42M	42M	42M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SIBN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	$2M	($1M)	($12M)	($19M)	($42M)	($40M)	($31M)	($32M)	($15M)	($18M)	($17M)	($27M)	($26M)	($1M)	($15M)
Capital Expenditures (CapEx)	$7M	$8M	$10M	$8M	$10M	$6M	$3M	$2M	$1M	$0M	$0M	$2M	$3M	$1M	$0M
Free Cash Flow (FCF)	($4M)	($9M)	($23M)	($27M)	($51M)	($46M)	($33M)	($34M)	($15M)	($18M)	($17M)	($29M)	($29M)	($1M)	($15M)
FCF Margin %	-2.1%	-4.5%	-13.7%	-19.1%	-48.1%	-50.9%	-45.3%	-50.6%	-27.9%	-37.5%	-40.8%	-70.3%	-72.9%	-2.7%	-40.0%
Dividends Paid	—	—	—	$2M	—	$5M	$2M	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SIBN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$1M	($2M)	$2M	$2M	$0M	($5M)	$1M	$0M
Capital Expenditures (CapEx)	$2M	$1M	$1M	$3M	$2M	$2M	$2M	$3M
Free Cash Flow (FCF)	($1M)	($3M)	$0M	($1M)	($2M)	($7M)	($1M)	($3M)
FCF Margin %	-1.4%	-6.5%	0.8%	-1.3%	-4.0%	-14.8%	-2.2%	-6.8%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SIBN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$249M	$239M	$230M	$230M	$158M	$191M	$223M	$117M	$139M	$36M	$39M	$36M	$29M	$18M
Cash & Cash Equivalents	$33M	$42M	$35M	$33M	$21M	$63M	$54M	$10M	$25M	$22M	$28M	$20M	$18M	$9M
Total Liabilities	$66M	$61M	$63M	$61M	$59M	$56M	$54M	$54M	$48M	$165M	$148M	$33M	$22M	$20M
Total Debt (Short + Long-Term)	$36M	$37M	$37M	$37M	$37M	$36M	$39M	$39M	$39M	$77M	$29M	$51M	$30M	$2M
Total Shareholders' Equity	$182M	$178M	$167M	$169M	$98M	$134M	$169M	$63M	$90M	($129M)	($109M)	$3M	$7M	($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SIBN viewer.

Other Companies in MEDICAL DEVICES

ENOV · Enovis Corp — $1 billion
CBLL · CeriBell, Inc — $935 million
BVS · Bioventus Inc — $882 million
INMD · InMode Ltd — $826 million
AVR · Anteris Technologies Global Corp. Common Stock — $809 million
VREX · Varex Imaging Corp — $779 million
AHCO · Adapthealth Corp — $760 million
QDEL · Quidel Corporation — $728 million

← SIAM All “S” companies SICAGEN →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.